NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $45.22 -1.88 (-3.99%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$44.91▼$47.4050-Day Range$44.91▼$53.5652-Week Range$30.18▼$54.10Volume189,152 shsAverage Volume440,547 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice Target$55.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vericel alerts: Email Address Vericel MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.3% Upside$55.75 Price TargetShort InterestBearish6.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.20Based on 5 Articles This WeekInsider TradingSelling Shares$3.10 M Sold Last QuarterProj. Earnings Growth430.00%From $0.10 to $0.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector419th out of 910 stocksBiological Products, Except Diagnostic Industry60th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vericel's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.46% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Vericel has recently increased by 4.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 3.4 News and Social Media Coverage News SentimentVericel has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vericel this week, compared to 4 articles on an average week.Search Interest1 people have searched for VCEL on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,101,269.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow by 430.00% in the coming year, from $0.10 to $0.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -4,517.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -4,517.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 9.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Vericel Stock (NASDAQ:VCEL)Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesSeptember 7 at 2:53 AM | americanbankingnews.comVericel (NASDAQ:VCEL) Rating Increased to Hold at StockNews.comAugust 29, 2024 | markets.businessinsider.comBuy Rating for Vericel on FDA Approval and Market Expansion PotentialSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 29, 2024 | globenewswire.comVericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024August 29, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) PT Raised to $60.00August 29, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) Shares Up 3.2% After Analyst UpgradeAugust 27, 2024 | finanznachrichten.deVericel Corporation: Vericel Announces FDA Approval and Commercial Availability of MACI ArthroAugust 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vericel Amidst FDA Approval and Promising MACI Arthro LaunchSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 27, 2024 | markets.businessinsider.comVericel’s Strategic Advancements Prompt Buy Rating: Expanding Market Reach with FDA-Approved MACI ArthroAugust 26, 2024 | globenewswire.comVericel Announces FDA Approval and Commercial Availability of MACI ArthroAugust 17, 2024 | finanznachrichten.deVericel Corporation: Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal BurnsAugust 17, 2024 | finance.yahoo.comMediWound and Vericel win FDA paediatric label expansion for NexoBridAugust 16, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Vericel (VCEL)August 15, 2024 | globenewswire.comVericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal BurnsAugust 10, 2024 | msn.comCanaccord Genuity Initiates Coverage of Vericel (VCEL) with Buy RecommendationAugust 7, 2024 | globenewswire.comVericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024August 6, 2024 | ca.finance.yahoo.comJPM Thematics Genetic Thrps A dist GBPH (0P0001INWU.L)See More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Stock Price Target$55.75 High Stock Price Target$60.00 Low Stock Price Target$42.00 Potential Upside/Downside+23.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio452.20 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins0.37% Pretax Margin0.75% Return on Equity0.35% Return on Assets0.22% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio4.16 Sales & Book Value Annual Sales$214.52 million Price / Sales10.25 Cash Flow$0.02 per share Price / Cash Flow2,931.00 Book Value$4.96 per share Price / Book9.12Miscellaneous Outstanding Shares48,602,000Free Float46,075,000Market Cap$2.20 billion OptionableOptionable Beta1.67 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 60)CEO, President & Director Comp: $1.54MMr. Joseph Anthony Mara Jr. (Age 48)CFO & Treasurer Comp: $750.61kMr. Michael Halpin (Age 62)Chief Operating Officer Comp: $796.91kMr. Sean C. Flynn (Age 50)Chief Legal Officer Comp: $657.01kDr. Jonathan M. Hopper FRCSEd. (Age 62)M.B. Ch.B., Chief Medical Officer Comp: $672.16kMr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate ControllerMr. Eric BurnsVice President of Finance & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporate Development & StrategyMr. Patrick HelfrichVice President of Marketing & Commercial StrategyMr. Mike GilliganSenior Vice President of SalesMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSREGENXBIONASDAQ:RGNXAlectorNASDAQ:ALECC4 TherapeuticsNASDAQ:CCCCBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 8,822 shares on 8/21/2024Ownership: 0.102%Algert Global LLCBought 4,632 shares on 8/16/2024Ownership: 0.010%Northwestern Mutual Wealth Management Co.Bought 2,103 shares on 8/16/2024Ownership: 0.008%The Manufacturers Life Insurance Company Bought 1,355 shares on 8/15/2024Ownership: 0.054%Susquehanna Portfolio Strategies LLCSold 1,413 shares on 8/15/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $35.61 at the start of the year. Since then, VCEL stock has increased by 27.0% and is now trading at $45.22. View the best growth stocks for 2024 here. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Vericel's revenue was up 14.8% on a year-over-year basis. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Vericel's major shareholders? Top institutional shareholders of Vericel include Conestoga Capital Advisors LLC (4.20%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.12%), William Blair Investment Management LLC (1.87%) and Federated Hermes Inc. (1.73%). Insiders that own company stock include Dominick Colangelo, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin, Sean C Flynn and Jonathan Mark Hopper. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). This page (NASDAQ:VCEL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
